HK Stock Market Move | XTALPI (02228) closed up more than 5% at the end of the day. The company has been included in the FTSE China Small Cap Index, and the commercialization of its AI pharmaceutical business is steadily advancing.

XTALPI (02228) rose more than 5% at the close, with a 4.55% increase at the time of writing, reaching HK$11.03, with a turnover of HK$1.487 billion. On the news front, recently, FTSE Russell updated the semi-annual adjustment list of the FTSE Global Equity Index series for September. XTALPI was included in the FTSE China Small Cap Index. The relevant adjustments officially took effect after the close on September 19. Analysis indicates that being included in international indices implies broader capital attention and liquidity premium. CMSC pointed out that XTALPI's AI pharmaceutical business is steadily progressing towards commercialization, with a year-on-year growth rate of up to 615% in drug discovery business in the first half of 2025. The company has maintained long-term partnerships with global top pharmaceutical companies such as Pfizer and Johnson & Johnson. The company, along with DoveTree, completed a pipeline cooperation contract with a total order scale of $5.99 billion, and has received an initial payment of $51 million as agreed in the contract, contributing to the increase in performance. By sharing quantum computing, multi-modal AI, and automation platforms, XTALPI has achieved cross-domain reuse of technical platforms, successfully expanding into multiple fields such as new energy, agriculture, and industrial materials.